Day: December 22, 2022

Fitch Ratings has today upgraded Statkraft’s rating to “A-” from “BBB+”, with a stable outlook. The upgrade is mainly driven by higher profits forecasted by Fitch. “Statkraft updated its growth strategy within renewable energy earlier this year, with more ambitious targets towards 2030. Strong credit ratings are important to be able to deliver on our strategy and optimize and expand our existing operations. We appreciate this positive rating action, but Statkraft stays committed to our rating target of A- from S&P and BBB+ from Fitch,” says Anne Harris, CFO of Statkraft. Contacts:Stephan Skaane, Vice President Group Treasury, phone +47 905 13 652Tron Ringstad, Senior Vice President Group Treasury, phone +47 992 93 670 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading...

Helsinki, Finland – December 22, 2022 – A major cybersecurity-focused USA-based Managed Service Provider (MSP) has selected SSH PrivX MSP Edition to control and monitor access to their data centers and their customers’ environments.  This new customer further strengthens PrivX’s position on the USA market. The initial contract value is approximately EUR 0.3 million of annual recurring subscription revenue (ARR), including professional services. The contract is automatically renewable.  Modern cyber-attacks require modern solutions The MSP customer selected PrivX over competing products for its modern and scalable architecture enabling automated and easy-to-use access governance to their managed services customers. The customer evaluated several vendors, including traditional leading Privileged Access Management (PAM) vendors...

        Company Announcement No 64/2022Peberlyk 46200 Aabenraa, Denmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk22 December 2022  Dear Sirs Sydbank A/S share buyback programme completed – transactions in week 51 Sydbank’s share buyback programme of DKK 425m which was announced on 2 March 2022 and scheduled to end on or before 30 December 2022 has been completed. Under the programme 1,887,000 own shares were repurchased at a transaction value of approx DKK 425m during the period up to termination. The purpose of the share buyback programme was to reduce the share capital of Sydbank and the programme was executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU)...

EfTEN Real Estate Fund III AS wishes to inform all investors of the fund’s financial calendar for the 2023 financial year. We plan to disclose financial results and organize the general meeting of shareholders according to the following schedule: 01/02/2023        Unaudited results for Q4 2022 and 12 months 2022 28/02/2023        Audited results for 2022 20/04/2023        General meeting of shareholders 27/04/2023        Q1 interim results 27/07/2023        Q2 interim results 26/10/2023        Q3 interim results Marilin Hein CFOPhone: 655 9515E-mail: marilin.hein@eften.ee

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.  The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The archived webcast will be available for approximately 30 days following the presentation date. About Axiomer® ProQR is pioneering a next-generation...

WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Wednesday, January 11th, 2023, at 3:45 PM PT. A webcast of the presentation will be available on the Events and Presentations section of ProKidney’s investor relations website at https://investors.prokidney.com/news-events/events-and-presentations. Investors attending the conference who are interested in meeting with ProKidney management may request a meeting by contacting their J.P. Morgan representative, or reaching out to Glenn Schulman at glenn.schulman@prokidney.com or Lee Roth at...

NoHo Partners Plc STOCK EXCHANGE RELEASE 22 DECEMBER 2022 at 12:00 EET The Board of Directors of NoHo Partners Plc has resolved on the fourth earning period of the long-term incentive plan for the company’s key employees NoHo Partners Plc’s Board of Directors has resolved on the fourth earning period of the long-term incentive plan for the company’s key employees. The fourth earning period is 24 months, starting on 1 January 2023, and ending on 31 December 2024. The reward criteria for the fourth earning period are based on NoHo Partners Plc’s profitable growth. There are ten participants in the long-term incentive plan’s fourth earning period. A maximum of 280,420 reward shares could be awarded for the fourth earning period. The value of the maximum reward at the average share price on the trading day preceding this stock...

Share Buyback Transaction Details December 15 – December 21, 2022 December 22, 2022 – Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 321,695 of its own ordinary shares in the period from December 15, 2022, up to and including December 21, 2022, for €32.6 million and at an average share price of €101.20. These repurchases are part of the share buyback program under which we intend to repurchase shares for €1 billion during 2022, as announced on August 3, 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2022 to date 9,958,326 983.1 ...

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023 FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira® and confirmed that the data provided are sufficient to support a determination of interchangeability; approval requires satisfactory outcome of upcoming facility reinspection Alvotech is anticipating a facility reinspection by the FDA in the first quarter of 2023Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the FDA has granted a new Biosimilar User Fee Amendment (BsUFA) goal date of April 13, 2023, for Alvotech’s original Biologics License Application...